抗毒蕈碱药物联合α受体阻滞剂治疗良性前列腺增生患者储尿症状的作用:一项更新的系统评价与Meta分析
该系统评价纳入12项随机安慰剂对照试验,评估抗毒蕈碱药物联合α受体阻滞剂治疗良性前列腺增生男性储尿症状的疗效与安全性。Meta分析显示,联合治疗未显著减少每日尿急次数,仅小幅减少每日排尿次数,但残余尿量轻微增加,且急性尿潴留、口干、便秘及因不良事件中断治疗的风险均升高。
要点
- 抗毒蕈碱药物联合α受体阻滞剂未显著减少每日尿急次数(SMD -0.23,P = .21)。
- 联合治疗小幅减少每日排尿次数(SMD -0.19,P = .045),但残余尿量轻微增加(SMD 0.26,P < .01)。
- 联合治疗急性尿潴留(RR 3.26)、口干(RR 3.43)、便秘(RR 2.92)及因不良事件中断治疗(RR 1.74)风险均升高。
核心结论
- 在α受体阻滞剂基础上加用抗毒蕈碱药物并未显著减少良性前列腺增生伴储尿症状患者的尿急和排尿次数,且毒性特征不支持使用抗毒蕈碱药物。
研究设计与样本
- 检索PubMed、MEDLINE、EMBASE和Cochrane数据库,纳入2022年2月15日前发表的随机安慰剂对照试验,评估抗毒蕈碱药物在α受体阻滞剂治疗的良性前列腺增生男性中的疗效或安全性。
- 共纳入12项随机试验进行系统评价,采用标准化均数差(SMD)和风险比(RR)进行Meta分析。
主要发现
- 抗毒蕈碱药物对每日尿急次数无影响(SMD -0.23 [95%CI: -0.64; -0.17];P = .21)。
- 抗毒蕈碱药物与每日排尿次数小幅减少相关(SMD -0.19 [95%CI: -0.37; -0.01];P = .045)。
- 使用抗毒蕈碱药物患者残余尿量轻微增加(SMD 0.26 [95%CI: 0.15; 0.37];P < .01)。
- 使用抗毒蕈碱药物患者急性尿潴留风险更高(RR 3.26 [95%CI: 1.35; 7.86];P = .02)。
- 使用抗毒蕈碱药物患者口干(RR 3.43 [95%CI: 1.86; 6.32];P < .001)、便秘(RR 2.92 [95%CI: 1.48; 5.73];P < .001)及因不良事件中断治疗(RR 1.74 [95%CI: 1.27; 2.38];P < .01)风险更高。
临床怎么用
- 原文结论指出,在α受体阻滞剂基础上加用抗毒蕈碱药物并未显著减少尿急和排尿次数,且毒性特征不支持使用抗毒蕈碱药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluate the efficacy and safety of combining antimuscarinics with alpha-blockers to treat storage symptoms in men with benign prostatic hyperplasia. MATERIALS AND METHODS: Searches were carried out on PubMed, MEDLINE, EMBASE, and Cochrane databases to identify randomized, placebo-controlled trials published before February 15, 2022, assessing the efficacy or safety of antimuscarinics in men with benign prostatic hyperplasia treated with alpha-blockers. Further meta-analyses were performed using standardized mean difference and risk ratio. RESULTS: A total of 12 randomized trials were included in the systematic review. The meta-analysis showed no impact of antimuscarinics on the number of urgencies per day (SMD -0.23 [95%CI: -0.64; -0.17]; P = .21). However, the use of antimuscarinics was associated with a small reduction of micturition episodes per day (SMD -0.19 [95%CI: -0.37; -0.01]; P = .045). With regard to side effects, post-void residual increased slightly in patients treated with antimuscarinics (SMD 0.26 [95%CI: 0.15; 0.37]; P < .01). In addition, there was a higher risk of acute urinary retention (RR 3.26 [95%CI: 1.35; 7.86]; P = .02), dry mouth (RR 3.43 [95%CI: 1.86; 6.32]; P < .001), and constipation (RR 2.92 [95%CI: 1.48; 5.73]; P < .001) with the use of antimuscarinics. Finally, the risk of treatment interruption due to adverse events was higher for the patients treated with antimuscarinics (RR 1.74 [95%CI: 1.27; 2.38]; P < .01). CONCLUSIONS: The addition of antimuscarinics to alpha-blockers was not associated with a substantial reduction in urgencies and micturition episodes in benign prostatic hyperplasia patients with storage symptoms. In addition, the toxicity profile was not in favor of antimuscarinic use in these patients.
引用
- Lenfant L, Pinar U, Roupret M, et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2022. PMID: 36395428. doi:10.1097/JU.0000000000003077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。